The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Characterization of OXA-25, OXA-26, and OXA-27, Molecular Class D β-Lactamases Associated with Carbapenem Resistance in Clinical Isolates of Acinetobacter baumannii
Open accessAbstract
Carbapenem resistance in Acinetobacter spp. is increasingly being associated with OXA-type β-lactamases with weak hydrolytic activity against imipenem and meropenem. Such enzymes were characterized from Acinetobacter isolates collected in Belgium, Kuwait, Singapore, and Spain. The isolates from Spain and Belgium had novel class D β-lactamases that were active against carbapenems. These were designated OXA-25 and OXA-26, respectively, and had >98% amino acid homology with each other and with the OXA-24 enzyme recently described by others from an Acinetobacter isolate collected elsewhere in Spain. The isolate from Singapore had OXA-27 β-lactamase, another novel class D type with only 60% homology to OXA-24, -25, and -26, but with 99% homology to OXA-23 (ARI-1), described previously from an Acinetobacter baumannii isolate collected in Scotland. Sequence data were not obtained for the carbapenem-hydrolyzing OXA enzyme from the isolate from Kuwait; nevertheless, the enzyme was phenotypically similar to OXA-25 and -26. The enzymes OXA-23, -24, -25, -26, and -27 retained the STFK and SXV motifs typical of class D β-lactamases, but the YGN motif was altered to FGN. The KTG motif was retained by OXA-27 and -23 but was replaced by KSG in OXA-24, -25, and -26. OXA-25 and -26 enzymes were strongly active against oxacillin, but unusually for an OXA-type β-lactamase, OXA-27 had apparently weak activity, although measurement was complicated by biphasic kinetics. None of the new enzymes was transmissible to Escherichia coli recipients. Many Acinetobacter isolates are multiresistant to other antibiotics, and the emergence of class D enzymes with carbapenem-hydrolyzing activity is a disturbing development for antimicrobial chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Thompson, J. D., Higgins, D. G., & Gibson, T. J. (1994) · Nucleic Acids Research · doi:10.1093/nar/22.22.4673 · Cited by 64,617
Rapid extraction of bacterial genomic DNA with guanidium thiocyanate
Pitcher, D. G., Saunders, N. A., & Owen, R. J. (1989) · Letters in Applied Microbiology · doi:10.1111/j.1472-765x.1989.tb00262.x · Cited by 2,145
Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features
Bergogne-Bérézin, E., & Towner, K. J. (1996) · Clinical Microbiology Reviews · doi:10.1128/cmr.9.2.148 · Cited by 1,711
Oefner, C., D'Arcy, A., Daly, J. J., Gubernator, K., Charnas, R. L., Heinze, I., Hubschwerlen, C., & Winkler, F. K. (1990) · Nature · doi:10.1038/343284a0 · Cited by 299
Senda, K., Arakawa, Y., Nakashima, K., Ito, H., Ichiyama, S., Shimokata, K., Kato, N., & Ohta, M. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.2.349 · Cited by 275
Bou, G., Oliver, A., & Martínez-Beltrán, J. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.6.1556-1561.2000 · Cited by 247
ARI 1: β-lactamase-mediated imipenem resistance in Acinetobacter baumannii
Paton, R., Miles, R. S., Hood, J., Amyes, S. G. B., Miles, R. S., & Amyes, S. G. B. (1993) · International Journal of Antimicrobial Agents · doi:10.1016/0924-8579(93)90045-7 · Cited by 245
Donald, H. M., Scaife, W., Amyes, S. G. B., & Young, H.-K. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.1.196-199.2000 · Cited by 235
Phylogeny of LCR‐1 and OXA‐5 with class A and class D β‐lactamases
Couture, F., Lachapelle, J., & Lévesque, R. C. (1992) · Molecular Microbiology · doi:10.1111/j.1365-2958.1992.tb00894.x · Cited by 149
Urban, C. M., Go, E., Mariano, N., & Rahal, J. J. (1995) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.1995.tb07357.x · Cited by 71
Cited by
Acinetobacter baumannii : Emergence of a Successful Pathogen
Peleg, A. Y., Seifert, H., & Paterson, D. L. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00058-07 · Cited by 3,316
Bradford, P. A. (2001) · Clinical Microbiology Reviews · doi:10.1128/cmr.14.4.933-951.2001 · Cited by 2,618
Carbapenemases: the Versatile β-Lactamases
Queenan, A. M., & Bush, K. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00001-07 · Cited by 2,499
Three Decades of β-Lactamase Inhibitors
Drawz, S. M., & Bonomo, R. A. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00037-09 · Cited by 1,709
Metallo-β-Lactamases: the Quiet before the Storm?
Walsh, T. R., Toleman, M. A., Poirel, L., & Nordmann, P. (2005) · Clinical Microbiology Reviews · doi:10.1128/cmr.18.2.306-325.2005 · Cited by 1,431
Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology
Poirel, L., & Nordmann, P. (2006) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2006.01456.x · Cited by 1,051
Lee, C.-R., Lee, J. H., Park, M., Park, K. S., Bae, I. K., Kim, Y. B., Cha, C.-J., Jeong, B. C., & Lee, S. H. (2017) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2017.00055 · Cited by 1,016
Emergence of Oxacillinase-Mediated Resistance to Imipenem in Klebsiella pneumoniae
Poirel, L., Héritier, C., Tolün, V., & Nordmann, P. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.1.15-22.2004 · Cited by 997
Maragakis, L. L., & Perl, T. M. (2008) · Clinical Infectious Diseases · doi:10.1086/529198 · Cited by 969
Bacterial Resistance to β-Lactam Antibiotics: Compelling Opportunism, Compelling Opportunity
Fisher, J. F., Meroueh, S. O., & Mobashery, S. (2005) · Chemical Reviews · doi:10.1021/cr030102i · Cited by 913
Evans, B. A., & Amyes, S. G. B. (2014) · Clinical Microbiology Reviews · doi:10.1128/cmr.00117-13 · Cited by 815
The role of ISAba1 in expression of OXA carbapenemase genes in Acinetobacter baumannii
Turton, J. F., Ward, M. E., Woodford, N., Kaufmann, M. E., Pike, R., Livermore, D. M., & Pitt, T. L. (2006) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.2006.00195.x · Cited by 751
Self-citationPotron, A., Poirel, L., & Nordmann, P. (2015) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2015.03.001 · Cited by 688
Emerging carbapenemases in Gram-negative aerobes
Nordmann, P., & Poirel, L. (2002) · Clinical Microbiology and Infection · doi:10.1046/j.1469-0691.2002.00401.x · Cited by 684
Diversity, Epidemiology, and Genetics of Class D β-Lactamases
Poirel, L., Naas, T., & Nordmann, P. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01512-08 · Cited by 632
Global evolution of multidrug-resistant Acinetobacter baumannii clonal lineages
Zarrilli, R., Pournaras, S., Giannouli, M., & Tsakris, A. (2013) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2012.09.008 · Cited by 496
Walther-Rasmussen, J., & Høiby, N. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki482 · Cited by 495
Emergence, molecular mechanisms and global spread of carbapenem-resistant Acinetobacter baumannii
Hamidian, M., & Nigro, S. J. (2019) · Microbial Genomics · doi:10.1099/mgen.0.000306 · Cited by 465
“Stormy waters ahead”: global emergence of carbapenemases
Patel, G., & Bonomo, R. A. (2013) · Frontiers in Microbiology · doi:10.3389/fmicb.2013.00048 · Cited by 423
Multidrug-resistant Acinetobacter baumannii as an emerging concern in hospitals
Ibrahim, S., Al-Saryi, N., Al-Kadmy, I. M. S., & Aziz, S. N. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06690-6 · Cited by 388
Multidrug-resistant Acinetobacter baumannii: mechanisms of virulence and resistance
Gordon, N. C., & Wareham, D. W. (2010) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2009.10.024 · Cited by 378
The Acinetobacter baumannii Oxymoron: Commensal Hospital Dweller Turned Pan-Drug-Resistant Menace
Roca, I., Espinal, P., Vila-Farrés, X., & Vila, J. (2012) · Frontiers in Microbiology · doi:10.3389/fmicb.2012.00148 · Cited by 363
Antimicrobial resistance in Acinetobacter baumannii: From bench to bedside
Lin, M.-F. (2014) · World Journal of Clinical Cases · doi:10.12998/wjcc.v2.i12.787 · Cited by 357
Antimicrobial resistance of Acinetobacter spp. in Europe
Van Looveren, M., & Goossens, H. (2004) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2004.00942.x · Cited by 327
Carbapenemases: a problem in waiting?
Livermore, D. M., & Woodford, N. (2000) · Current Opinion in Microbiology · doi:10.1016/s1369-5274(00)00128-4 · Cited by 323
Self-citationCarbapenemases: Molecular Diversity and Clinical Consequences
Poirel, L., Pitout, J. D., & Nordmann, P. (2007) · Future Microbiology · doi:10.2217/17460913.2.5.501 · Cited by 309
Bacterial Resistance to Antimicrobial Agents
Varela, M. F., Stephen, J., Lekshmi, M., Ojha, M., Wenzel, N., Sanford, L. M., Hernandez, A. J., Parvathi, A., & Kumar, S. H. (2021) · Antibiotics · doi:10.3390/antibiotics10050593 · Cited by 292
Characterization of the Naturally Occurring Oxacillinase of Acinetobacter baumannii
Héritier, C., Poirel, L., Fournier, P.-E., Claverie, J.-M., Raoult, D., & Nordmann, P. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.10.4174-4179.2005 · Cited by 286
Héritier, C., Poirel, L., Lambert, T., & Nordmann, P. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.8.3198-3202.2005 · Cited by 272
Leavitt, A., Navon-Venezia, S., Chmelnitsky, I., Schwaber, M. J., & Carmeli, Y. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00299-07 · Cited by 256
The ABCD’s of β-lactamase nomenclature
Bush, K. (2013) · Journal of Infection and Chemotherapy · doi:10.1007/s10156-013-0640-7 · Cited by 239
“[20], with class D motifs later identified as the families of class D enzymes increased [21, 22].”
BackgroundDesigning Irreversible Inhibitors—Worth the Effort?
González‐Bello, C. (2016) · ChemMedChem · doi:10.1002/cmdc.201500469 · Cited by 74
Metadata
- Authors
- Afzal-Shah, M., Woodford, N., & Livermore, D. M.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2001-02
- Volume
- 45
- Issue
- 2
- Pages
- 583-588
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2163192834
- Cited by
- 282
- References
- 10
- FWCI
- 8.96
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.